Literature DB >> 11159702

Differential modulation by GTPgammaS of agonist and inverse agonist binding to h5-HT(1A) receptors revealed by [3H]-WAY100,635.

A Newman-Tancredi1, L Verrièle, M J Millan.   

Abstract

1. The interaction of serotonergic ligands at human (h) 5-HT(1A) receptors expressed in Chinese hamster ovary cells was examined with the selective 'neutral' 5-HT(1A) antagonist [(3)H]-WAY100,635. Its binding was saturable (K(D)=0.056 nM) with a B(max) (3.65 pmol mg(-1)) significantly higher than that of two other selective 5-HT(1A) radioligands: the partial agonist, [(3)H]-S15535 (2.77 pmol mg(-1)) and the agonist, [(3)H]-8-OH-DPAT (2.02 pmol mg(-1)). 2. The influence of GTPgammaS (100 microM) on the binding affinity of 15 serotonergic agonists, partial agonists, antagonists and inverse agonists was investigated in competition binding experiments with [(3)H]-WAY100,635. 3. Agonists, including 5-HT, 8-OH-DPAT and buspirone, displayed biphasic isotherms which shifted to the right in the presence of GTPgammaS. In contrast, isotherms of the inverse agonists, methiothepin, (+)butaclamol and spiperone, were shifted to the left in the presence of GTPgammaS. Unlabelled WAY100,635 was the only ligand that was unaffected by GTPgammaS, consistent with 'neutral' antagonist properties. 4. The magnitude of affinity changes induced by GTPgammaS for 13 ligands was highly correlated (r = 0.98) with their efficacy (positive and negative) previously determined by [(35)S]GTPgammaS binding. 5. In contrast, the napthylpiperazine derivative and high efficacy agonist, S14506, displayed only a modest GTPgammaS shift, in accordance with previous indications of 'atypical' binding properties of this ligand. A further full agonist, S14671, which is chemically closely-related to S14506, also displayed a minimal GTPgammaS shift, underpinning this observation. 6. In conclusion, [(3)H]-WAY100,635 constitutes a useful neutral antagonist radioligand for the characterization of drug actions at h5-HT(1A) receptors. GTPgammaS-induced affinity changes of agonist and inverse agonist competition isotherms generally correlate well with ligand efficacy, with the notable exception of two chemically-similar agents, S14506 and S14671, which are efficacious agonists, yet relatively insensitive to h5-HT(1A) receptor/G-protein coupling changes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11159702      PMCID: PMC1572578          DOI: 10.1038/sj.bjp.0703832

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  33 in total

Review 1.  Inverse agonism at heptahelical receptors: concept, experimental approach and therapeutic potential.

Authors:  L Daeffler; Y Landry
Journal:  Fundam Clin Pharmacol       Date:  2000 Mar-Apr       Impact factor: 2.748

2.  S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties.

Authors:  M J Millan; S Hjorth; R Samanin; R Schreiber; R Jaffard; B De Ladonchamps; S Veiga; B Goument; J L Peglion; M Spedding; M Brocco
Journal:  J Pharmacol Exp Ther       Date:  1997-07       Impact factor: 4.030

3.  Labelling of recombinant human and native rat serotonin 5-HT1A receptors by a novel, selective radioligand, [3H]-S 15535: definition of its binding profile using agonists, antagonists and inverse agonists.

Authors:  A Newman-Tancredi; L Verrièle; C Chaput; M J Millan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1998-03       Impact factor: 3.000

4.  Correlation between low/high affinity ratios for 5-HT(1A) receptors and intrinsic activity.

Authors:  M B Assié; C Cosi; W Koek
Journal:  Eur J Pharmacol       Date:  1999-12-10       Impact factor: 4.432

5.  Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors.

Authors:  C Egan; E Grinde; A Dupre; B L Roth; M Hake; M Teitler; K Herrick-Davis
Journal:  Synapse       Date:  2000-02       Impact factor: 2.562

6.  Mechanisms of agonism and inverse agonism at serotonin 5-HT1A receptors.

Authors:  D J McLoughlin; P G Strange
Journal:  J Neurochem       Date:  2000-01       Impact factor: 5.372

7.  The putative <<silent>> 5-HT(1A) receptor antagonist, WAY 100635, has inverse agonist properties at cloned human 5-HT(1A) receptors.

Authors:  C Cosi; W Koek
Journal:  Eur J Pharmacol       Date:  2000-07-28       Impact factor: 4.432

8.  5-HT(1A) receptor agonist-antagonist binding affinity difference as a measure of intrinsic activity in recombinant and native tissue systems.

Authors:  J Watson; L Collin; M Ho; G Riley; C Scott; J V Selkirk; G W Price
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

9.  Atypical in vitro and in vivo binding of [3H]S-14506 to brain 5-HT1A receptors.

Authors:  L Lima; A M Laporte; C Gaymard; M Spedding; E Mocaër; M Hamon
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

10.  Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.

Authors:  A Newman-Tancredi; S Gavaudan; C Conte; C Chaput; M Touzard; L Verrièle; V Audinot; M J Millan
Journal:  Eur J Pharmacol       Date:  1998-08-21       Impact factor: 4.432

View more
  5 in total

1.  [(3)H]-F13640, a novel, selective and high-efficacy serotonin 5-HT(1A) receptor agonist radioligand.

Authors:  Peter Heusler; Christiane Palmier; Stéphanie Tardif; Sophie Bernois; Francis C Colpaert; Didier Cussac
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-08-27       Impact factor: 3.000

2.  Similar anxiolytic effects of agonists targeting serotonin 5-HT1A or cannabinoid CB receptors on zebrafish behavior in novel environments.

Authors:  Kristin A Connors; Theodore W Valenti; Kelly Lawless; James Sackerman; Emmanuel S Onaivi; Bryan W Brooks; Georgianna G Gould
Journal:  Aquat Toxicol       Date:  2013-12-12       Impact factor: 4.964

3.  Evaluation of [C]S14506 and [F]S14506 in rat and monkey as agonist PET radioligands for brain 5-HT(1A) receptors.

Authors:  Shuiyu Lu; Jeih-San Liow; Sami S Zoghbi; Jinsoo Hong; Robert B Innis; Victor W Pike
Journal:  Curr Radiopharm       Date:  2010-01

4.  Contractile effects of 5-hydroxytryptamine and 5-carboxamidotryptamine in the equine jejunum.

Authors:  Cathérine Delesalle; Piet Deprez; Jan A J Schuurkes; Romain A Lefebvre
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

5.  Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924.

Authors:  A Newman-Tancredi; J-M Rivet; D Cussac; M Touzard; C Chaput; L Marini; M J Millan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-08-16       Impact factor: 3.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.